Alison Skrinar Selected Research

burosumab

1/2022	Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
1/2022	Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
1/2021	Validation of the Radiographic Global Impression of Change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH).
1/2021	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
1/2019	Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
1/2019	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
1/2018	Burosumab Therapy in Children with X-Linked Hypophosphatemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alison Skrinar Research Topics

Disease

7	Familial Hypophosphatemic Rickets (X-Linked Hypophosphatemia) 01/2022 - 01/2018
7	Rickets (Rachitis) 01/2022 - 01/2018
5	Pain (Aches) 04/2022 - 01/2018
5	Muscular Diseases (Myopathy) 01/2019 - 04/2010
4	Congenital Abnormalities (Deformity) 01/2022 - 01/2018
3	Hypophosphatemia 01/2022 - 01/2018
3	Glycogen Storage Disease Type II (Pompe's Disease) 04/2010 - 04/2007
2	Body Weight (Weight, Body) 01/2018 - 04/2010
1	Hyperparathyroidism 04/2022
1	Nephrocalcinosis 04/2022
1	Abscess 01/2022
1	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2022
1	Fatigue 01/2021
1	Wasting Syndrome (Wasting Disease) 01/2021
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2018
1	Distal Myopathies (Distal Muscular Dystrophy) 01/2018
1	Osteomalacia 01/2018
1	Nonaka type Distal myopathy 01/2017
1	Anaphylaxis (Anaphylactic Shock) 04/2010
1	Vomiting 04/2010
1	Urticaria (Hives) 04/2010
1	Flushing 04/2010
1	Hyperhidrosis 04/2010

Drug/Important Bio-Agent (IBA)

8	Phosphates (Orthophosphate)IBA 01/2022 - 01/2018
7	burosumabIBA 01/2022 - 01/2018
6	Fibroblast Growth Factor-23IBA 01/2022 - 01/2018
5	Phosphorus (Red Phosphorus)IBA 01/2021 - 01/2018
4	Monoclonal AntibodiesIBA 01/2022 - 01/2018
4	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2019 - 01/2016
4	AcidsIBA 01/2019 - 04/2007
3	Vitamin D FDA LinkGeneric 01/2022 - 07/2019
2	Alkaline PhosphataseIBA 01/2022 - 01/2021
2	EnzymesIBA 01/2017 - 04/2010
2	GlycogenIBA 04/2010 - 04/2007
2	alpha-Glucosidases (Acid Maltase)IBA 04/2010 - 04/2007
2	human GAA protein (Myozyme)FDA Link 04/2010 - 03/2009
1	SaltsIBA 01/2022
1	Calcitriol (Calcijex)FDA LinkGeneric 01/2022
1	CreatinineIBA 01/2019
1	PHEX Phosphate Regulating Neutral EndopeptidaseIBA 01/2019
1	Pharmaceutical PreparationsIBA 04/2010

Therapy/Procedure

5	Therapeutics 04/2022 - 01/2018
1	Parathyroidectomy 04/2022